OncoMatch/Clinical Trials/NCT06376721
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Is NCT06376721 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Linperlisib and Camrelizumab for natural killer/t-cell lymphoma, nasal and nasal-type.
Treatment: Linperlisib · Camrelizumab · Pegaspargase · Dexamethasone — The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received:
refractory or relapsed after initial remission
Cannot have received: PI3K inhibitor
Patients has received PI3K inhibitor treatment before enrollment
Lab requirements
Blood counts
wbc ≥ 3×10e9/l, plt ≥ 75×10e9/l, anc ≥ 1.5×10e9/l
Kidney function
scr ≤ 1.5 mg/dl, gfr ≥ 50 ml/min
Liver function
alt & ast ≤ 3 times the upper limit of normal, tbil ≤ 2 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify